Table 9.

Health care resource use by events/days among patients with AML

Study	Data collection years	Patient group	Mean follow-up, months	Mean age, years	Total patients, N	Number of events, mean				Number of days, mean
						Inpatient admissions	ER visits	Outpatient visits	Pharmacy claims	Total inpatient days	Length of stay per admission
PPPM
Griffin et al. 2018 [112]	2012-2017	RR	11.1 (median)	57.7a	304	0.28	NR	NR	NR	NR	NR
Griffin et al. 2019 [113]	2013-2016	RR	9.0	53.2: FLT3 mut	363	0.52	0.54	7.2	NR	6.5	NR
				56.8: FLT3 wt
Hagiwara et al. 2018 [106]	2007-2016	Achieved remission	15.73	55.3b	2481	0.143	0.067	4.7	3.66	1.43	NR
		Relapsed	10.49	55.3b	1460	0.224	0.098	6.84	4.5	3.79	NR
Per patient for total follow-up
Hagiwara et al. 2018 [106]	2007-2016	Achieved remission	6.08	55.3	NR	0.87	0.41	28.6	22.3	8.7	NR
		Relapsed	2.39	55.3	NR	0.54	0.23	16.3	10.8	9	NR
Irish et al. 2017 [52]	2009-2015	First-line, achieved remission	17.1	51.4	681	2.1	1.1	18.6	NR	37	NR
		Relapsed, achieved remission	11.5	52.2	70	1	0.3	11.2	NR	18.5	NR
Pandya et al. 2019 [108]	2007-2016	All RR	15	52	707	4.5	3.4	76.8	83.1	75	17
		RR with HSCT	16.8	51.2	476	4.9	3.7	89.9	102.9	87	18
		RR without HSCT	11.1	53.6	231	3.6	2.6	49.7	42.8	46	14

Note: None of the studies provided statistical comparisons of resource use between patient groups. Abbreviations: AML, acute myeloid leukemia; ER, emergency room; HSCT, hematopoietic stem cell transplantation; mut, mutated; NR, not reported; PPPM, per-patient-per-month; RR, relapsed or refractory; wt, wild type.

^aMean age was only provided for the overall population.

^bMean age was only provided for treated patients.